Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Short Interest Down 47.5% in February

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) was the recipient of a significant drop in short interest in February. As of February 15th, there was short interest totalling 1,460,000 shares, a drop of 47.5% from the January 31st total of 2,780,000 shares. Approximately 5.9% of the company’s stock are sold short. Based on an average daily volume of 2,750,000 shares, the days-to-cover ratio is presently 0.5 days.

Tevogen Bio Stock Performance

TVGN stock opened at $1.28 on Friday. The business has a 50 day moving average price of $1.34 and a two-hundred day moving average price of $1.13. Tevogen Bio has a twelve month low of $0.26 and a twelve month high of $8.49.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. bought a new position in shares of Tevogen Bio during the 4th quarter worth approximately $38,000. JPMorgan Chase & Co. boosted its stake in shares of Tevogen Bio by 74.2% during the 4th quarter. JPMorgan Chase & Co. now owns 39,207 shares of the company’s stock worth $40,000 after acquiring an additional 16,695 shares during the period. Barclays PLC boosted its stake in shares of Tevogen Bio by 39.2% during the 4th quarter. Barclays PLC now owns 45,600 shares of the company’s stock worth $48,000 after acquiring an additional 12,847 shares during the period. XTX Topco Ltd bought a new position in shares of Tevogen Bio during the 4th quarter worth approximately $55,000. Finally, Northern Trust Corp boosted its stake in shares of Tevogen Bio by 13.0% during the 4th quarter. Northern Trust Corp now owns 118,415 shares of the company’s stock worth $122,000 after acquiring an additional 13,595 shares during the period.

About Tevogen Bio

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.